ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

30 Apr 2025 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

22 Apr 2025 15:59:59 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

09 Apr 2025 09:15:25 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

08 Apr 2025 14:57:55 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

07 Apr 2025 08:45:16 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

04 Apr 2025 09:30:54 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

02 Apr 2025 08:45:05 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

01 Apr 2025 08:49:27 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

31 Mar 2025 08:47:05 By NetDania Notify

NetDania - New 12 months Low: ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

26 Mar 2025 10:11:30 By NetDania Notify

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Mar 2025 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Investor Conferences in March

24 Feb 2025 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Feb 2025 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

18 Feb 2025 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

13 Feb 2025 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update

06 Feb 2025 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

05 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 Jan 2025 15:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

12 Jan 2025 10:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 15:30:00 By Nasdaq GlobeNewswire